Oral administration of irinotecan in patients with solid tumors: an open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics

I. Kümler^*, P. Grundtvig Sørensen, J. Palshof, E. Høgdall, W. Skovrider-Ruminski, S. Theile, A. Fullerton, P. G. Nielsen, B. Vittrup Jensen, D. L. Nielsen

^*Corresponding author for this work